SIRT1 and breast carcinoma: SIRT1-FL deacetylation activity is fine-tuned by several mechanisms [43], including interaction with the SIRT1-FL activator AROS (Active Regulator Of SIRT1–FL)[44], and the SIRT1-FL-inhibitor DBC-1 (Deleted in Breast Cancer-1)[45], [46].